MY203647A - Sustained-release dosage forms of ruxolitinib - Google Patents
Sustained-release dosage forms of ruxolitinibInfo
- Publication number
- MY203647A MY203647A MYPI2018002592A MYPI2018002592A MY203647A MY 203647 A MY203647 A MY 203647A MY PI2018002592 A MYPI2018002592 A MY PI2018002592A MY PI2018002592 A MYPI2018002592 A MY PI2018002592A MY 203647 A MY203647 A MY 203647A
- Authority
- MY
- Malaysia
- Prior art keywords
- ruxolitinib
- sustained
- dosage forms
- release dosage
- useful
- Prior art date
Links
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 title abstract 2
- 229960000215 ruxolitinib Drugs 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders. [FIGURE 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI2018002592A MY203647A (en) | 2015-05-12 | 2015-05-12 | Sustained-release dosage forms of ruxolitinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI2018002592A MY203647A (en) | 2015-05-12 | 2015-05-12 | Sustained-release dosage forms of ruxolitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY203647A true MY203647A (en) | 2024-07-11 |
Family
ID=94479872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018002592A MY203647A (en) | 2015-05-12 | 2015-05-12 | Sustained-release dosage forms of ruxolitinib |
Country Status (1)
| Country | Link |
|---|---|
| MY (1) | MY203647A (en) |
-
2015
- 2015-05-12 MY MYPI2018002592A patent/MY203647A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
| MY199968A (en) | Formulations of an lsd1 inhibitor | |
| MY195561A (en) | Indole Carboxamide Compounds useful as Kinase Inhibitors | |
| WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
| EA201791009A1 (en) | COMPOSITIONS CONTAINING CYCLOSPORIN | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| PH12016501205B1 (en) | Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency | |
| PH12017500743A1 (en) | Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency | |
| HK1243709A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| MY203647A (en) | Sustained-release dosage forms of ruxolitinib | |
| WO2016144706A3 (en) | Autotaxin inhibitor compounds and uses thereof | |
| PH12019501070A1 (en) | Sustained-release dosage forms of ruxolitinib | |
| WO2018229551A3 (en) | Methods to treat opioid use disorder | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| TW201613563A (en) | Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof | |
| HK1209575A2 (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2016010919A (en) | 4-benzylsulfonyl-2-butenenitrile. |